Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy

NCT04290663 is registered in ClinicalTrials.gov with Centre Francois Baclesse as lead sponsor.

NCT NCT04290663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04290663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy
Lead sponsor
Centre Francois Baclesse
Phase
Phase 3
Overall status
Recruiting
Start date
March 2, 2020
Completion date
February 28, 2033
Enrollment
368 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

intermediate risk, thyroid cancer